-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SUxIcFg5lgSQM49j+vYC8H+/gsLMdzz+vcxvawwfAeQWPFF979byS6U5PuG2e9QB awIENyyoKGq4vpVQx7DHlg== 0000912057-02-035375.txt : 20020913 0000912057-02-035375.hdr.sgml : 20020913 20020912173449 ACCESSION NUMBER: 0000912057-02-035375 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020906 ITEM INFORMATION: Other events FILED AS OF DATE: 20020913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEORX CORP CENTRAL INDEX KEY: 0000755806 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911261311 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-16614 FILM NUMBER: 02762915 BUSINESS ADDRESS: STREET 1: 410 W HARRISON ST CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 206-286-25 MAIL ADDRESS: STREET 1: 410 W HARRISON ST CITY: SEATTLE STATE: WA ZIP: 98119 8-K 1 a2089170z8-k.htm 8-K
QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

September 6, 2002
(Date of Report)

NEORX CORPORATION
(Exact Name of Registrant as Specified in Charter)

Washington	0-16614	91-1261311
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)
410 West Harrison Street, Seattle, Washington		98119-4007
(Address of principal executive offices)		(Zip Code)

(206) 281-7001
(Registrant's telephone number, including area code)

Item 5. Other Events

On September 6, 2002, NeoRx Corporation received a letter from the Nasdaq Stock Market notifying it that the closing bid price per share for NeoRx common stock was below $1.00 for 30 consecutive trading days and that as a result the company no longer meets the continued listing criteria. NeoRx has until December 5, 2002 to regain compliance with the listing criteria. To regain compliance with the minimum bid price requirement, the closing bid price of its common shares must remain above $1.00 for a minimum of ten consecutive trading days. NeoRx management and Board of Directors are considering various alternatives to address this issue.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		NEORX CORPORATION
Dated: September 13, 2002		By	/s/ RICHARD L. ANDERSON Richard L. Anderson Senior V-P, CFO and Secretary

QuickLinks

SIGNATURE
-----END PRIVACY-ENHANCED MESSAGE-----